LUPIN (LUPIN) News
Follow LUPIN (LUPIN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Four blue-chip stocks in India with expanding margins
New Delhi, Sept. 29 -- When it comes to investing, blue-chip stocks are often associated with established companies that have built a strong track record over the years. These companies typically have a large market pres
NEWS | Sep 29, 2026, 03:36 AM UTC
L
Lupin Limited (LUPIN) Gets FDA Tentative Nod for Apixaban Oral Suspension
Lupin Limited received tentative U.S. FDA approval for its 505(b)(2) Apixaban Oral Suspension 1.25 mg/mL. Final approval is pending; manufacturing would occur at its Somerset, New Jersey facility.Material DetailsContext
REGULATION | Sep 28, 2026, 01:11 PM UTC
L
Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension
MUMBAI, India and NAPLES, Fla., Sept. 28, 2026 // -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE:LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative appr
REGULATION | Sep 28, 2026, 01:10 PM UTC
L
Lupin Receives Tentative U.S. FDA Approval For Apixaban Oral Suspension 1.25Mg/Ml Via 505(B)(2)
Lupin Limited NSE:LUPIN
REGULATION | Sep 28, 2026, 04:38 AM UTC
M
HSBC cuts Lupin price target 10% but keeps Buy
HSBC lowered its Lupin price target by 10% to ₹2,500 from ₹2,770, citing valuation concerns, while keeping a “buy” recommendation. Shares fell on Tuesday, Sept. 22.
EQUITY | Sep 22, 2026, 07:51 AM UTC
L
Lupin rises after Nomura reaffirms Buy and Rs 2,675 target
Nomura reaffirmed its Buy rating on Lupin and a target price of Rs 2,675. By 11:10 am, the stock was at Rs 2,070.20 on the NSE, up Rs 25.20 (1.23%).
EQUITY | Sep 17, 2026, 05:51 AM UTC
L
Eris, Torrent Pharma, Natco, Lupin stand out in Rs157 billion India GLP-1 opportunity: Kotak
Eris Lifesciences, Torrent Pharma, Natco Pharma and Lupin are expected to see the highest contribution to FY2029E earnings per share from India's GLP-1 opportunity, at 4-12%, according to Kotak Institutional Equities. Su
EARNINGS | Sep 10, 2026, 05:41 AM UTC
M
Lupin shares in focus after USFDA approval for modafinil tablets
Lupin said the US Food and Drug Administration approved its modafinil tablets, aimed at improving wakefulness in adult patients with excessive sleepiness. The stock will remain in focus on September 7.
EQUITY | Sep 07, 2026, 02:06 AM UTC
M
Lupin gets US FDA approval for modafinil 100 mg and 200 mg tablets
Lupin said the US FDA approved its Modafinil Tablets USP in 100 mg and 200 mg strengths. The regulator approved the tablets as bioequivalent to Provigil Tablets, the reference listed drug of Nuvo Pharma.
REGULATION | Sep 04, 2026, 12:47 PM UTC
M
Lupin receives U.S. FDA approval for modafinil tablets, USP
Lupin Limited received U.S. FDA approval for modafinil tablets, USP.
REGULATION | Sep 04, 2026, 12:15 PM UTC
M
Lupin slips after Citi downgrade; ICICI Pru AMC drops on block deal
Lupin shares fell after Citi downgraded to sell. ICICI Pru AMC slipped 3% on a block deal.
EQUITY | Aug 27, 2026, 04:46 AM UTC
M
Lupin wins ruling on Vertex cystic fibrosis patents
A ruling has gone in favor of Lupin regarding Vertex patents related to a cystic fibrosis drug, according to TradingView News.
EQUITY | Aug 26, 2026, 08:37 AM UTC